Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

08 Feb 2016 - 10 Feb 2016
11 Feb 2016 - 12 Feb 2016
18 Feb 2016 - 20 Feb 2016

Rapid Diagnosis Possible at POC

By Labmedica International staff writers
Posted on 05 Mar 2013
Print article
Image: The hand-held cobas h 232 is suitable for use in different clinical settings, from the General Practitioner’s office to the Emergency Room (Photo courtesy of Roche).
Image: The hand-held cobas h 232 is suitable for use in different clinical settings, from the General Practitioner’s office to the Emergency Room (Photo courtesy of Roche).
A versatile handheld device enables rapid diagnosis at point of care (POC).

In hospitals, Roche's (Burgess, United Kingdom) products can support laboratory services by providing accurate diagnosis of patient samples and enabling rapid diagnosis of medical conditions in the emergency ward, intensive care, and in the operating theatre.

Forth Valley Royal Hospital (United Kingdom) has reduced lengths of stay and ward admissions for patients presenting with chest pain, as well as ensuring rapid referral for patients with positive findings, through the introduction of a Chest Pain Assessment Unit (CPAU). This unit provides patient care and rapid access to diagnostic testing, including Troponin T testing, using the Roche point of care (POC) cardiac marker system, cobas h 232.

“Prior to opening the CPAU, patients at low risk of Acute Coronary Syndrome (ACS) were spending a long time in hospital unnecessarily, often overnight, while ACS was ruled out,” explained nurse consultant-acute medicine, Sharon Oswald. “To obtain real-time results that enable rapid decisions to be made, we introduced the Roche cobas h 232 system for point-of-care Troponin T testing. The cobas h 232 has had a huge impact on the service. Before we introduced it, Troponin T tests were batched and performed four times per day in the laboratory. There were sometimes delays in getting the bloods to the laboratory and then in getting results back. Now, with the cobas h 232 systems, we are able to obtain results in real time, which allows faster decision making.”

“The cobas h 232 system is very sensitive,” Sharon added. “A six month comparative evaluation demonstrated that we were getting comparable results to the laboratory method. We still send positives to the laboratory for confirmation but negative results do not require further confirmation. This means [we can exclude] ACS more quickly, allowing earlier discharge. Patients that require further investigation or care can be referred immediately or given a planned return appointment.”

Related Links:
Roche
Forth Valley Royal Hospital



Print article

Channels

Immunology

view channel
Image: Micrograph of prostatic adenocarcinoma with perineural invasion, conventional (acinar) type, the most common form of prostate cancer. Prostate biopsy, H&E stain (Photo courtesy of Nephron and Wikimedia).

Reduced PSA Screening May Delay Treatment for Earlier Onset Prostate Cancers

The recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for 2.5 years. The number of prostate needle biopsies (PNB) has been reduced and... Read more

Industry News

view channel

Abbott to Gain Leadership in POC Diagnostics upon Acquisition of Alere

Abbott Inc. (Abbott Park, IL, USA) and Alere Inc. (Waltham, MA, USA) have reached a definitive agreement under which Abbott will pay an equity value of about USD 5.8 billion to acquire Alere. Once the transaction is completed, Abbott will become leading diagnostics provider of point-of-care (POC) testing.... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.